现代肿瘤医学
現代腫瘤醫學
현대종류의학
Journal of Modern Oncology
2015年
22期
3286-3289
,共4页
李东辉%王海鹏%孙华%李超
李東輝%王海鵬%孫華%李超
리동휘%왕해붕%손화%리초
原发性肝癌%重组人p53 基因腺病毒注射液%TACE
原髮性肝癌%重組人p53 基因腺病毒註射液%TACE
원발성간암%중조인p53 기인선병독주사액%TACE
primary liver cancer%restructuring of p53 adenovirus injection%TACE
目的:研究重组人 p53腺病毒注射液(商品名:今又生)在原发性肝癌介入治疗中的安全性及有效性。方法:61例中晚期原发性肝癌患者,分两组介入治疗:对照组:碘油+化疗药(5-FU +EPI +DDP);治疗组:碘油+化疗药(5-FU +EPI +DDP)+重组人 p53基因腺病毒注射液;每4周一次,连用3次。结果:不论是对照组还是治疗组,毒副反应不大,耐受性良好,生活质量均有一定的提高;治疗后两组均能使原发性肝癌的肿瘤标志物 AFP 下降,但治疗组下降明显;治疗组的有效率(82.76%)明显高于对照组(59.38%),统计学检验差异显著。结论:今又生介入治疗原发性肝癌安全有效,值得推广。
目的:研究重組人 p53腺病毒註射液(商品名:今又生)在原髮性肝癌介入治療中的安全性及有效性。方法:61例中晚期原髮性肝癌患者,分兩組介入治療:對照組:碘油+化療藥(5-FU +EPI +DDP);治療組:碘油+化療藥(5-FU +EPI +DDP)+重組人 p53基因腺病毒註射液;每4週一次,連用3次。結果:不論是對照組還是治療組,毒副反應不大,耐受性良好,生活質量均有一定的提高;治療後兩組均能使原髮性肝癌的腫瘤標誌物 AFP 下降,但治療組下降明顯;治療組的有效率(82.76%)明顯高于對照組(59.38%),統計學檢驗差異顯著。結論:今又生介入治療原髮性肝癌安全有效,值得推廣。
목적:연구중조인 p53선병독주사액(상품명:금우생)재원발성간암개입치료중적안전성급유효성。방법:61례중만기원발성간암환자,분량조개입치료:대조조:전유+화료약(5-FU +EPI +DDP);치료조:전유+화료약(5-FU +EPI +DDP)+중조인 p53기인선병독주사액;매4주일차,련용3차。결과:불론시대조조환시치료조,독부반응불대,내수성량호,생활질량균유일정적제고;치료후량조균능사원발성간암적종류표지물 AFP 하강,단치료조하강명현;치료조적유효솔(82.76%)명현고우대조조(59.38%),통계학검험차이현저。결론:금우생개입치료원발성간암안전유효,치득추엄。
Objective:To study the efficacy and safety of restructuring of p53 adenovirus injecttion in the primary liver cancer underwenttranscatheter arterial chemoembolization,TACE.Methods:Sixty one patients were diagnosed as primary liver cancer,pathologically.All patients underwent transcatheter arterial chemoembolization,TACE and were randomized divided into two groups,the control group was treated by iodine oil +chemotherapy drugs(5 -FU +EPI +DDP),the treatment group withiodine oil +chemotherapy drugs(5 -FU +EPI +DDP)+restructuring of p53 adenovi-rus injection.The efficacy,quality of life(QOL),and adverse reactions were evaluated.Results:In two groups,the re-liability safety was similar,life quality was enhanced,and the tumor mark was decinling.The effective rates of two groups were 59.38% and 82.76%,the treatment group was superior to the control group(P <0.05).Conclusion:U-sing restructuring of p53 adenovirus injectionon the interventional therapyin the primary liver cancer,can increase ef-fective rate.